SEARCH

SEARCH BY CITATION

References

  • 1
    Reimund JM, Wittersheim C, Dumont S, et al. Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 1996; 39: 6849.
  • 2
    Pucilowska JB, Williams KL, Lund PK. Fibrogenesis. IV. Fibrosis and inflammatory bowel disease: cellular mediators and animal models. Am J Physiol Gastrointest Liver Physiol 2000; 279: G6539.
  • 3
    Hassan C, Zullo A, Campo S, Morini S. New insights into the biological therapy of Crohn’s disease. Expert Opinion on Therapeutic Patents 2005; 15: 40919.
  • 4
    Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 13508.
  • 5
    McKaig BC, Hughes K, Tighe PJ, Mahida YR. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol 2002; 282: C17282.
  • 6
    Beddy D, Mulsow J, Watson RW, Fitzpatrick JM, O’connell PR. Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn’s disease. Br J Surg 2006; 93: 12906.
  • 7
    Graham MF, Willey A, Adams J, Yager D, Diegelmann RF. Interleukin 1 beta down-regulates collagen and augments collagenase expression in human intestinal smooth muscle cells. Gastroenterology 1996; 110: 34450.
  • 8
    Van Assche G, Geboes K, Rutgeerts P. Medical therapy for Crohn’s disease strictures. Inflamm Bowel Dis 2004; 10: 5560.
  • 9
    Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn’s disease. Ann Surg 2000; 231: 3845.
  • 10
    Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn’s disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88: 181825.
  • 11
    Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G. Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25: 66572.
  • 12
    Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn’s disease. Experience with 1379 patients. Ann Surg 1991; 214: 2308.
  • 13
    Ardizzone S, Maconi G, Sampietro GM, et al. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology 2004; 127: 73040.
  • 14
    Fearnhead NS, Chowdhury R, Box B, George BD, Jewell DP, Mortensen NJ. Long-term follow-up of strictureplasty for Crohn’s disease. Br J Surg 2006; 93: 47582.
  • 15
    Breysem Y, Janssens JF, Coremans G, Vantrappen G, Hendrickx G, Rutgeerts P. Endoscopic balloon dilation of colonic and ileo-colonic Crohn’s strictures: long-term results. Gastrointest Endosc 1992; 38: 1427.
  • 16
    Travis SP, Stange EF, Lemann M, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: current management. Gut 2006; 55: i1635.
  • 17
    Kaila VL, El-Newihi HM, Mihas AA. Successful endoscopic dilation of a Crohn’s colonic stricture. Gastrointest Endosc 1996; 44: 35960.
  • 18
    Dear KL, Hunter JO. Colonoscopic hydrostatic balloon dilatation of Crohn’s strictures. J Clin Gastroenterol 2001; 33: 3158.
  • 19
    Sabate JM, Villarejo J, Bouhnik Y, et al. Hydrostatic balloon dilatation of Crohn’s strictures. Aliment Pharmacol Ther 2003; 18: 40913.
  • 20
    Williams AJ, Palmer KR. Endoscopic balloon dilatation as a therapeutic option in the management of intestinal strictures resulting from Crohn’s disease. Br J Surg 1991; 78: 4534.
  • 21
    Ferlitsch A, Reinisch W, Puspok A, et al. Safety and efficacy of endoscopic balloon dilation for treatment of Crohn’s disease strictures. Endoscopy 2006; 38: 4837.
  • 22
    Brooker JC, Beckett CG, Saunders BP, Benson MJ. Long-acting steroid injection after endoscopic dilation of anastomotic Crohn’s strictures may improve the outcome: a retrospective case series. Endoscopy 2003; 35: 3337.
  • 23
    Matsui T, Hatakeyama S, Ikeda K, Yao T, Takenaka K, Sakurai T. Long-term outcome of endoscopic balloon dilation in obstructive gastroduodenal Crohn’s disease. Endoscopy 1997; 29: 6405.
  • 24
    Thomas-Gibson S, Brooker JC, Hayward CM, Shah SG, Williams CB, Saunders BP. Colonoscopic balloon dilation of Crohn’s strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol 2003; 15: 4858.
  • 25
    Ramboer C, Verhamme M, Dhondt E, Huys S, Van Eygen K, Vermeire L. Endoscopic treatment of stenosis in recurrent Crohn’s disease with balloon dilation combined with local corticosteroid injection. Gastrointest Endosc 1995; 42: 2525.
  • 26
    Couckuyt H, Gevers AM, Coremans G, Hiele M, Rutgeerts P. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn’s strictures: a prospective longterm analysis. Gut 1995; 36: 57780.
  • 27
    Morini S, Hassan C, Lorenzetti R, et al. Long-term outcome of endoscopic pneumatic dilatation in Crohn’s disease. Dig Liver Dis 2003; 35: 8937.
  • 28
    Blomberg B, Rolny P, Jarnerot G. Endoscopic treatment of anastomotic strictures in Crohn’s disease. Endoscopy 1991; 23: 1958.
  • 29
    Singh VV, Draganov P, Valentine J. Efficacy and safety of endoscopic balloon dilation of symptomatic upper and lower gastrointestinal Crohn’s disease strictures. J Clin Gastroenterol 2005; 39: 28490.
  • 30
    Morini S, Hassan C, Cerro P, Lorenzetti R. Management of an ileocolic anastomotic stricture using polyvinyl over-the-guidewire dilators in Crohn’s disease. Gastrointest Endosc 2001; 53: 3846.